ERYP - Erytech drops plans to pursue FDA approval for leukemia therapy

• French biotech ERYTECH Pharma S.A. ( NASDAQ: ERYP ) announced Wednesday that it would no longer seek U.S. approval for Graspa in hypersensitive acute lymphoblastic leukemia (ALL) following the feedback the company received from the FDA.
• Chief Executive Gil Beyen noted that the shift in the competitive environment and additional resources required to respond to the new data request from the FDA have led to the decision to discontinue further development of Graspa in ALL.
• The company now shifts the focus on its most promising preclinical programs and plans to explore strategic partnering options to maximize value for staff and shareholders, Beyen added.

For further details see: